Clinical Trial

A Phase II Trial of LM103 in Advanced Melanoma

Name: A Phase II Trial of LM103 in Advanced Melanoma — clinical trial record (NCT07310784)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A total of 92 subjects with advanced melanoma who met the inclusion criteria will be randomly assigned in a 1:1 ratio to the experimental group and the control group in this phase II trial. The study will be followed up until 24 months after treatment.

Protocol Amendment History 1 change

notable Trial sites expanded: 1 -> 13 locations 2026-05-13

Trial Details

NCT Number	NCT07310784
Lead Sponsor	Suzhou BlueHorse Therapeutics Co., Ltd.
Conditions	Advanced Melanoma
Enrollment	92 participants
Start Date	2025-12-16
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-12